DDReg pharma

Quailty Driven by Passion

Regulatory

Home » Insights » Regulatory » Page 2

Quality Assurance and Compliance

Ensuring that products and services meet the highest standards of quality and compliance is crucial, and Quality Assurance (QA) plays a pivotal role in achieving this. At DDReg Pharma Pvt Ltd, the QA department is an integral part of the organization’s success. The department focuses on delivering services that exceed customer expectations while adhering to […]

Quality Assurance and Compliance Read More »

Navigating Drug Manufacturing Inspections

The US FDA conducts drug manufacturing inspections for facilities to ensure they are compliant with the Current Good Manufacturing Practice (cGMP) standards. However, navigating through these inspections requires a clear and comprehensive understanding of several aspects. These include applicable manufacturing standards, site selection model, 483 forms, and how the FDA reviews the inspections and outcomes.

Navigating Drug Manufacturing Inspections Read More »

How does EMA use Artificial Intelligence and Large Language Models in Medicine Regulation?

Artificial Intelligence in Medicine Regulation– a perspective by Emer Cooke, Executive Director of the European Medicines Agency. Introduction Artificial Intelligence (AI) is revolutionizing the regulation of medicines by offering innovative solutions to enhance drug safety, efficacy, and overall patient well-being. With its ability to process vast amounts of data, identify patterns, and predict potential risks,

How does EMA use Artificial Intelligence and Large Language Models in Medicine Regulation? Read More »

Guidance on Informed Consent in Clinical Investigations

Within the realm of clinical research, the process of obtaining informed consent stands as a crucial cornerstone of ethical practice, serving to protect the rights and well-being of human participants. The U.S. Food and Drug Administration (FDA) recognizes the changing landscape of clinical investigations and the necessity to align with the 2018 Common Rule and

Guidance on Informed Consent in Clinical Investigations Read More »

Drug Application Pathway

Understanding the FDA’s Abbreviated New Animal Drug Application Pathway

The level of scrutiny surrounding animal medicinal products has strengthened more adverse events (AEs) associated with such products have emerged in animals. Indeed, AEs and adverse drug reactions (ADRs) is a cause of concern for veterinarians. Several cases of toxicity from commonly used drugs have been reported, in canines, for example. These include licosamides that

Understanding the FDA’s Abbreviated New Animal Drug Application Pathway Read More »

Public Health Emergencies

Mitigating medical device shortages in public health emergencies

The onset of the pandemic amplified an already growing concern in the European Union (EU)- the shortage of medicines, equipment, and devices that subsequently burdens the health system and puts patients at risk. Some of the reasons for these kinds of shortages are related to problems in manufacturing that can delay production, shortages of raw

Mitigating medical device shortages in public health emergencies Read More »

Digitalization in Regulatory Affairs

Digitalization in Regulatory Affairs

Technology is rapidly driving the growth of the Pharmaceutical and Life Sciences industries. With digital solutions being made more easily available, drug development & pharmacovigilance are transforming to become more efficient, compliant, and patient safety focused. However, regulatory affairs is still somewhat manual where processes and tasks are repetitive, siloed, and resource-heavy. Though Life Sciences

Digitalization in Regulatory Affairs Read More »

regulatory framework for cell, tissue, and gene therapy products

Convergence of regulatory frameworks surrounding cell, tissue, and gene therapy products

Cell, tissue, or gene therapy products (CTGTPs) can contain non-viable or viable human cells or tissues, viable animal cells or tissues, or recombinant nucleic acids and are intended for use in humans to treat, prevent, or even diagnosis conditions that are associated with high treatment burden [1]. However, regulations surrounding CTGTPs vary per region as

Convergence of regulatory frameworks surrounding cell, tissue, and gene therapy products Read More »

Impact of Russia Ukraine war on clinical Trails

The impact of the Russia-Ukraine war on clinical trials

The Russia-Ukraine war has undoubtedly affected millions of people in and around the world. Several industries have taken a huge hit where operational and business continuity has been threatened, the pharmaceutical industry being one of them. From the delays along the drug development pipeline, to non-compliance products in the market being at risk, the industry

The impact of the Russia-Ukraine war on clinical trials Read More »

DDReg RegTech space

DDReg’s RegTech space: your regulatory solution for achieving rapid market access

DDreg RegTech focuses on technologies that may facilitate the delivery of regulatory requirements more efficiently and effectively than existing capabilities. The global adoption of RegTech is a result of increased regulatory scrutiny, compliance costs, development of artificial intelligence, evolution of data science and increasing demands regarding cost-effective compliance solutions. With ever changing regulatory requirements, pharmaceutical

DDReg’s RegTech space: your regulatory solution for achieving rapid market access Read More »